Abstracts

899 – Decreased Adipose Tissue Gene Expression After a 48-Week Switch From an InSTI Regimen to TDF/3TC/DOR

Background INSTIs are known to induce weight/fat gain, the pathogenesis and reversibility of which remain unclear. The ongoing ADDORE study aimed to evaluate the evolution of adipose tissue (AT) between baseline and W48 in PWH with INSTI-associated weight gain switched to TDF/3TC/DOR. We present here preliminary adipocyte gene expression results. Methods PWH underwent two surgical…

863 – Impact of Antidiabetic Medications on Weight Change Among People With HIV

Background While novel antidiabetic medications like glucagon like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated weight loss in the general population, data on their impact on weight loss in PWH remains limited.  Methods We identified adult PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort who…

905 – Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance

Background People with HIV (PWH) are at elevated risk for type 2 diabetes (T2D), despite viral suppression. While obesity is a well-known driver of T2D in the general population, HIV-specific factors, such as chronic inflammation and antiretroviral therapy (ART), may contribute to risk in PWH. While subcutaneous adipose tissue (SAT) fibrosis promotes insulin resistance in…

900 – In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens

Background We previously demonstrated in a 3T3L1cells in vitro model of adipogenesis, that Integrase Strand Transfer Inhibitors (INSTI) increase adipogenesis, while, tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF), displayed an inhibitory effect, counteracting increased adipogenesis caused by INSTIs [dolutegravir (DTG), bictegravir (BIC)]. Deregulation of the expression levels of two families of adipocyte differentiation transcription factors, the CCAAT/enhancer-binding proteins (C/EBPs) and the…

893 – Body Composition Changes in People With HIV Switching From or Maintaining TDF-Based Regimens

Background Weight gain might occur in people with HIV (PWH) switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-based antiretroviral therapy (ART), but data regarding body composition are missing. The objective of the study was to explore body composition (BC) changes in PWH switching from or maintaining TDF-based ART. Methods This was anobservational longitudinal…